Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

August 29th 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

August 29th 2024

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLL

August 28th 2024

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL

August 26th 2024

BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.

Dr Koff on BTK Inhibitors vs Venetoclax-Based Regimens in First-Line CLL

August 23rd 2024

Jean L. Koff, MD, MS, discusses considerations around using BTK inhibitors vs venetoclax-based regimens in first-line chronic lymphocytic leukemia.

Dr Danilov on Unmet Needs for Various CLL Subgroups

August 22nd 2024

Alexey Danilov, MD, PhD discusses unmet needs for patients with chronic lymphocytic leukemia.

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

August 22nd 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

August 22nd 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Dr Tedeschi on the Initial Efficacy of Zanubrutinib Plus Venetoclax in Del 17p/TP53–Mutant CLL/SLL

August 21st 2024

Alessandra Tedeschi, MD, discusses the utility of zanubrutinib plus venetoclax in patients with CLL/SLL harboring deletion 17p and/or TP53 mutations.

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia

August 16th 2024

Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

August 15th 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

August 15th 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Dr Bertossi on the Role of Centralized Academic Reference Diagnostics and Biobanking in Clinical Trials

August 14th 2024

Consuelo Bertossi, MD, discusses centralized academic reference diagnostics and biobanking in prospective, multicenter clinical trials.

Dr Tedeschi on Long-Term Data With First-Line Ibrutinib in CLL

August 13th 2024

Alessandra Tedeschi, MD, discusses 10-year follow-up data on treatment with first-line ibrutinib in treatment-naive chronic lymphocytic leukemia.

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

August 13th 2024

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

August 12th 2024

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

August 12th 2024

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Dr Shadman on the Investigation of Sonrotoclax Combination Therapy in Treatment-Naive CLL

August 12th 2024

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

Sonrotoclax/Zanubrutinib Leads to Durable Responses in R/R CLL/SLL

August 12th 2024

Stephen Opat, MBBS, discusses data for sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Pirtobrutinib Produces Responses in BTK Inhibitor–Naive R/R CLL/SLL

August 6th 2024

Pirtobrutinib generated responses in BTK inhibitor–naive relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.